Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Discuss Approval of Individual Fertility Drugs after August
July 26, 2021
- Label Revisions Ordered for Evenity, Other Bone Disease Drugs
July 21, 2021
- Wariness Brewing within MHLW for Medical Fee to Incentivize Hospital Formularies
July 21, 2021
- Japan to Receive 50 Million More Doses of Moderna Vaccine
July 21, 2021
- New Generic Target Seems “Conservative Goal”, Dispensing Premium Revision Is a Must: Budget Examiner
July 20, 2021
- Key MOF Official Wants Budget Neutrality, Cap to Optimize Drug Costs
July 20, 2021
- Prefectural Governors Push AstraZeneca Vaccine Use
July 20, 2021
- Japan Approves COVID-19 Antibody Cocktail, 1st Drug for Mild Cases
July 20, 2021
- Takeda’s Pevonedistat Up for Discussion for 1st Legally Backed Sakigake Designation
July 19, 2021
- Lilly’s Selpercatinib, Rinvoq’s Eczema Use Up for PAFSC Review on July 30
July 19, 2021
- Japan Expands Supply of AstraZeneca’s COVID-19 Vaccine to Asian Nations
July 19, 2021
- New Pharma Industry Vision to Set Out Roles of Wholesalers: MHLW Director
July 16, 2021
- Snap Inspections at Generic Plants Conducted in 46 Prefectures, Results Due Out in August
July 16, 2021
- Japan to Lower Moderna Vaccine’s Minimum Age to 12
July 16, 2021
- MHLW Unmet Needs Council OKs Public Knowledge-Based Filings for 2 Antiemetics
July 15, 2021
- ICMRA Discussing Substitutes for Placebo-Controlled Trials of COVID Vaccines: MHLW
July 15, 2021
- Forxiga’s CKD Indication Up for PAFSC Review on July 28, Possible OK in August
July 15, 2021
- Chugai’s Antibody Cocktail Up for PAFSC Review on July 19, 4th COVID-19 Drug If Approved
July 13, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
July 9, 2021
- Japan PM “Watching Expert Discussions” on AstraZeneca Vaccine Use
July 9, 2021
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…